nerandomilast

**Nerandomilast** is an oral small-molecule preferential phosphodiesterase 4B inhibitor developed by **Boehringer Ingelheim** for fibrosing interstitial lung diseases. By preferentially inhibiting **PDE4B**, it increases intracellular cAMP signaling and is described as having antifibrotic and immunomodulatory effects, including reduction of profibrotic growth factors and inflammatory cytokines. The drug was developed for **idiopathic pulmonary fibrosis** and **progressive pulmonary fibrosis**, and U.S. public sources identify it as marketed under the brand **JASCAYD** for adult patients; additional ongoing development includes other interstitial lung disease settings such as systemic autoimmune rheumatic disease-associated ILD, scleroderma-associated ILD, familial pulmonary fibrosis risk settings, and pediatric fibrosing ILD.

Brand names

JASCAYD

Other names

nerandomilastBI1015550BI-1015550BI 1015550